Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 155

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 7
Chunk 155
---
 combination of equity offerings, debt financings, collaborations and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common shareholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common shares. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves. 

92

Cash Flows 

Comparison of the Years Ended December 31, 2024 and 2023

The following table summarizes our cash flows for each of the years presented: 

    Year endedDecember 31,

    2024

    2023

    CHANGE

    (in thousands)

    Net cash used in operating activities
     
    $
    (76,445
    )
     
    $
    (127,158
    )
     
    $
    50,713

    Net cash provided by investing activities

    49,468

    78,041

    (28,573
    )

    Net cash provided by financing activities

    542

    842

    (300
    )

    Effect of exchange rate fluctuations on cash held

    (116
    )

    22

    (138
    )

    Net Decrease In Cash And Cash Equivalents
     
    $
    (26,551
    )
     
    $
    (48,253
    )
     
    $
    21,702

Operating Activities 

Net cash used in operating activities was $76.4 million for the year ended December 31, 2024, reflecting a net loss of $84.7 million, a net decrease of $14.1 million in our net operating assets offset